Braveheart Bio Closes Upsized IPO at $18, Raises $439.9M After Full Overallotment Exercise
BRVE is trading near its 52-week low of $28.465 (8.8% above the low) on light trading volume (0.3× avg).
Summary
Braveheart Bio closed its upsized IPO, selling 24.44 million shares at $18.00 for gross proceeds of $439.9 million after underwriters fully exercised their overallotment option. This follows yesterday's pricing announcement of 21.25 million shares and $382.5 million, with the additional 3.19 million shares reflecting strong demand. The stock began trading on Nasdaq on August 6 and is near its 52-week high of $32, well above the IPO price, signaling robust aftermarket appetite. The capital infusion strengthens the balance sheet for advancing lead candidate BHB-1893 in hypertrophic cardiomyopathy. No specific upcoming catalysts are noted.
At the time of this announcement, BRVE was trading at $30.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $28.47 to $32.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.